Welcome to our dedicated page for BioSig Technologies news (Ticker: BSGM), a resource for investors and traders seeking the latest updates and insights on BioSig Technologies stock.
BioSig Technologies Inc. (NASDAQ: BSGM) provides cutting-edge solutions in cardiac electrophysiology through its flagship PURE EP™ System. This page serves as the definitive source for official company news, including financial results, regulatory milestones, and clinical advancements.
Investors and healthcare professionals will find curated updates on product innovations, partnership announcements, and peer-reviewed research validating BioSig's signal processing technology. Key coverage areas: quarterly earnings reports, FDA clearances, hospital adoption metrics, and intellectual property developments.
All content undergoes strict verification to ensure alignment with SEC disclosure standards and medical device reporting regulations. Bookmark this page for real-time updates on BSGM's progress in enhancing cardiac ablation accuracy through advanced signal visualization technology.
BioSig Technologies has appointed Gray Fleming as Chief Commercial Officer to enhance its market presence in electrophysiology. With over 20 years of healthcare experience, including leadership roles at Abbott Laboratories, Fleming aims to leverage his expertise to boost sales and market share of the PURE EP™ System, a non-invasive device designed for cardiac procedures. The company reports positive clinical data, showing a 75% improvement in signal quality. BioSig is currently focused on launching the PURE EP™ in key U.S. markets, including the Northeast, Texas, and Florida.
BioSig Technologies, Inc. (Nasdaq: BSGM) announced its participation in The Benchmark Company 10th Annual Discovery One on One Investor Conference on December 2, 2021. The company's leadership will update investors on the rollout of their FDA-cleared PURE EP™ System, which enhances procedural efficiency in cardiac electrophysiology. Over 1700 patient cases have been completed by 73 physicians using this system. The event will also discuss results from a recent clinical trial during a roundtable on November 18, 2021.
BioSig Technologies (NASDAQ: BSGM) announced a partnership with the Technion Research & Development Foundation for AI-driven research on atrial fibrillation procedures. The feasibility study will utilize data from BioSig's PURE EP(tm) System to develop predictive algorithms for arrhythmia care. Atrial fibrillation affects over 33 million globally, with significant healthcare costs. BioSig's technology aims to enhance procedural efficiency in cardiac electrophysiology, with ongoing clinical data supporting its effectiveness.
BioSig Technologies (Nasdaq: BSGM) will host a live roundtable webinar on November 18, 2021, discussing results from the PURE EP 2.0 study recently published in the Journal of Cardiovascular Electrophysiology. The event, titled “PURE EP 2.0 Study Results: From Clinical Data to Clinical Applications,” will feature experts Andrea Natale, Amin Al-Ahmad, and Wendy Tzou, who will review the impact of high-fidelity signals on cardiac ablation procedures. The study reported a 75% improvement in intracardiac signal quality and a 93% consensus among blinded reviewers.
BioSig Technologies has announced the installation of its PURE EP™ System at the highly-ranked Medical City Heart Hospital in Dallas, TX, marking its 17th installation and fifth in Texas. The facility focuses on advanced cardiovascular care, making it an ideal site for the technology aimed at improving ECG signal fidelity. Over 71 physicians have already utilized the system in over 1600 patient cases. A recent multi-center study published in the Journal of Cardiovascular Electrophysiology showed a 75% improvement in signal quality using the PURE EP™ System.
BioSig Technologies announces the installation of a PURE EP™ System at Beth Israel Deaconess Medical Center, increasing its installed centers to 16. The evaluation is expected to begin in December 2021. To date, over 71 physicians have conducted more than 1,600 cases with the system, indicating growing adoption. Clinical data shows a 75% improvement in intracardiac signal quality. With 33 million people affected by atrial fibrillation globally, BioSig aims to capitalize on this significant market through its innovative technology.
BioSig Technologies (Nasdaq: BSGM) announced a new installation agreement for its PURE EP(tm) System at Methodist Hospital in San Antonio, TX, enhancing its presence in the key Texas market. This agreement marks the Company’s 15th installed center, with Methodist Hospital being a high-volume provider of cardiac ablation procedures. The PURE EP(tm) System has shown significant clinical benefits, including a 75% improvement in signal quality according to recent studies. The Company continues to focus on expanding its technology across strategic regions in the Northeast, Texas, and Florida.
BioSig Technologies, Inc. (NASDAQ: BSGM) reported significant growth in the adoption of its PURE EP™ System for arrhythmia care, surpassing its target with over 1,560 patient cases recorded as of October 21, 2021. This marks an increase from 1,000 cases in June 2021. The company anticipates completing between 1,700 and 1,800 procedures by year-end, boosted by declining COVID-19 hospitalization rates. Clinical research published in the Journal of Cardiovascular Electrophysiology indicated a 75% improvement in intracardiac signal quality, showcasing the technology's clinical value.
BioSig Technologies, Inc. (NASDAQ: BSGM) announced its signal processing technology will be featured during the 16th Annual International Symposium on Ventricular Arrhythmias on October 15-16, 2021. The company’s PURE EP™ System, designed to enhance ECG signal clarity, has been instrumental in over 1500 patient cases across 13 clinical sites. Preliminary clinical data reveal a 75% overall improvement in intra-cardiac signal quality. The event is co-hosted by the University of Pennsylvania and The Mount Sinai Hospital, targeting professionals involved in ventricular arrhythmia management.
BioSig Technologies, Inc. (NASDAQ: BSGM) announced significant findings from the PURE EP 2.0 study, validating their PURE EP™ System as superior in intracardiac signal quality compared to conventional methods. Conducted across three major U.S. hospitals, the study involved 51 cardiac ablation procedures and achieved a 93% consensus among blinded reviewers. Results indicated a 75% improvement in signal quality, and an 83% enhanced confidence in interpreting complex signals. With over 60 physicians engaged in 1400 cases, BioSig aims to leverage these results for growth in electrophysiology and bioelectronic medicine.
FAQ
What is the current stock price of BioSig Technologies (BSGM)?
What is the market cap of BioSig Technologies (BSGM)?
